Medtronic (MDT) Rises As Market Takes a Dip: Key Facts

07.08.25 23:45 Uhr

Werte in diesem Artikel
Aktien

80,06 EUR -1,44 EUR -1,77%

Indizes

PKT PKT

17.903,5 PKT 111,4 PKT 0,63%

3.312,5 PKT 14,0 PKT 0,42%

6.643,7 PKT 39,0 PKT 0,59%

In the latest close session, Medtronic (MDT) was up +2.1% at $91.24. This move outpaced the S&P 500's daily loss of 0.08%. On the other hand, the Dow registered a loss of 0.51%, and the technology-centric Nasdaq increased by 0.35%. Shares of the medical device company witnessed a gain of 0.4% over the previous month, beating the performance of the Medical sector with its loss of 3.99%, and underperforming the S&P 500's gain of 1.21%.The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on August 19, 2025. In that report, analysts expect Medtronic to post earnings of $1.23 per share. This would mark no growth from the year-ago period. Meanwhile, our latest consensus estimate is calling for revenue of $8.37 billion, up 5.73% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of $5.55 per share and revenue of $35.29 billion, which would represent changes of +1.09% and +5.22%, respectively, from the prior year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.01% lower. As of now, Medtronic holds a Zacks Rank of #3 (Hold). Looking at valuation, Medtronic is presently trading at a Forward P/E ratio of 16.11. This indicates a discount in contrast to its industry's Forward P/E of 17.56. We can also see that MDT currently has a PEG ratio of 2.32. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. MDT's industry had an average PEG ratio of 2.19 as of yesterday's close. The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 156, placing it within the bottom 37% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Medtronic

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Medtronic

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Medtronic PLC

Wer­bung

Analysen zu Medtronic PLC

DatumRatingAnalyst
04.02.2019Medtronic Strong BuyNeedham & Company, LLC
03.01.2019Medtronic BuyDeutsche Bank AG
16.10.2018Medtronic OverweightBarclays Capital
22.08.2018Medtronic HoldStifel, Nicolaus & Co., Inc.
13.08.2018Medtronic Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
04.02.2019Medtronic Strong BuyNeedham & Company, LLC
03.01.2019Medtronic BuyDeutsche Bank AG
16.10.2018Medtronic OverweightBarclays Capital
22.08.2018Medtronic HoldStifel, Nicolaus & Co., Inc.
13.08.2018Medtronic Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
01.06.2016Medtronic NeutralWedbush Morgan Securities Inc.
23.11.2012Medtronic holdDeutsche Bank Securities
22.11.2012Medtronic neutralCredit Suisse Group
22.11.2012Medtronic neutralJP Morgan Chase & Co.
21.11.2012Medtronic sector performRBC Capital Markets
DatumRatingAnalyst
22.08.2007Medtronic underweightMorgan Stanley
29.09.2006Update Kyphon Inc.: UnderweightMorgan Stanley

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Medtronic PLC nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen